November 20, 2012
What happens when the FDA approval process slows down and imposes higher hurdles, when cost-reduction becomes central to the healthcare provider business model, when clinical trials and commercialization costs for medical devices and biotechnology products spiral through the roof, and when exit returns are compressed by general economic conditions and the decline of the IPO […]
Read the full article →
November 20, 2012
20 November 2012 | By Ben Hunt A great proportion of world economic activity is organised through giant global corporations. How managers govern them, and allocate resources, should at least in theory be of interest. For investors, ‘corporate governance’ – although not the most exciting of terms – is of central importance for enjoying a […]
Read the full article →